May 18, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Coya 302 gets fast-track designation for ALS treatment
The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a pretty devastating disease,” Fred Grossman, DO, FAPA, president and chief medical officer of Coya Therapeutics, told Healio. “People who have ALS will die essentially between 2 and 5 years after being diagnosed.”
857 words~4 min read
